Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Core Points - Sarepta Therapeutics, Inc. announced an update to the prescribing information for ELEVIDYS, the only approved gene therapy for Duchenne muscular dystrophy (DMD) [1] - The updated label now includes a boxed warning for the risk of acute serious liver injury (ALI) and acute liver failure (ALF) [1]